Evidence map›Paper›PMID 38217608›Full record

ArticleJournal of neuromuscular diseases2024

Burden of Disease of Duchenne Muscular Dystrophy in Denmark - A National Register-Based Study of Individuals with Duchenne Muscular Dystrophy and their Closest Relatives.

Jan Håkon Rudolfsen, John Vissing, Ulla Werlauff, Charlotte Olesen, Niels Illum, Jens Olsen, Peter Bo Poulsen, Mette Strand, Alfred Peter Born

Open access · hybridAbstract read
In one paragraph

Article in Journal of neuromuscular diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Jan Håkon RudolfsenEY, Copenhagen, Denmark.
John VissingCopenhagen Neuromuscular Center, Copenhagen University Hospital, Copenhagen, Denmark.
Ulla WerlauffThe Danish Rehabilitation Centre for Neuromuscular Diseases, Aarhus, Denmark.
Charlotte OlesenCenter for Rare Diseases and Neuropediatric Department, Aarhus University Hospital, Aarhus, Denmark.
Niels IllumH. C. Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
Jens OlsenEY, Copenhagen, Denmark.
Peter Bo PoulsenHealth & Value, Pfizer Denmark, Ballerup, Denmark.
Mette StrandMedical Affairs, Pfizer Denmark, Ballerup, Denmark.
Alfred Peter BornDepartment of Child- and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark.
Copenhagen University Hospital · DKAarhus University Hospital · DKDanish Pain Research Center · DKLeo Pharma (Denmark) · DKOdense University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Duchenne Muscular Dystrophy (DMD) is a progressive genetic disease with a prevalence of 1 per 3,600-6,000 male births. Individuals with DMD are typically diagnosed at age 4-7 years; median survival is 30 years. They require multidisciplinary care, personal assistance, and often special education. Objective: The aim was to assess the burden of disease in DMD in Denmark. This includes incidence, prevalence, use of healthcare services, labour market participation, educational outcomes, and overall attributable costs due to DMD. Impact on the closest relatives (siblings and parents) was also investigated. Methods: The comprehensive Danish national health and administrative registers were used to assess the burden of disease following individuals with DMD and closest relatives from five years before, and up to 20 years after DMD diagnosis. Individuals with DMD (and relatives) from 1994-2021 were included. All outcomes were compared to matched control groups without the disease drawn from the Danish population. Results: 213 unique individuals with DMD were identified. They had lower grades in school, required more special education and more healthcare and home care compared to their control group. The extra costs of special education summed to EUR 180,900 over the course of 11 years elementary school. They had an annual average productivity loss of EUR 20,200 between the age of 18 to 30. The extra healthcare costs of DMD in the 20 years after diagnosis were estimated to EUR 1,524,000. If an individual with DMD lives to be 30, total extra costs sum to EUR 2,365,800. Conclusions: Using national register data this study presented detailed results on the burden of disease of DMD, including impact on closest relatives. With 60 additional hospital admissions and 200 extra outpatient contacts in 20 years healthcare costs, but also costs of home care and special education, increases as disease progresses.

Indexed as

Muscular Dystrophy, DuchenneChildChild, PreschoolCost of IllnessDelivery of Health CareDenmarkHumansMaleParentscostcost of illnessduchenneeducationincidenceMuscular dystrophyparentspopulationprevalenceproductivityregisterssiblings

Identifiers

PMID38217608
PMCPMC10977402
OpenAlexW4390796659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.